共 61 条
[1]
Giustina A(2014)Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors Expert Opin Investig Drugs 23 1619-1635
[2]
Mazziotti G(2009)Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months Clin Pharmacokinet 48 51-62
[3]
Maffezzoni F(1999)Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency Clin Pharmacol Ther 66 485-491
[4]
Amoroso V(2014)Lanreotide in metastatic enteropancreatic neuroendocrine tumors N Engl J Med 371 224-233
[5]
Berruti A(2013)Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study BMC Cancer 13 427-251
[6]
Trocóniz IF(2004)Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide Neuroendocrinology 80 244-257
[7]
Cendrós JM(2005)PsN-Toolkit—a collection of computer intensive statistical methods for nonlinear mixed effect modeling using NONMEM Comput Methods Programs Biomed 79 241-445
[8]
Peraire C(1994)Comparison of the akaike information criterion, the schwarz criterion and the J Pharmacokinet Pharmacodyn 22 431-377
[9]
Ramis J(2004) test as guides to model selection Br J Clin Pharmacol 58 367-64
[10]
Garrido MJ(1999)Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis Comput Methods Programs Biomed 58 51-20